




Contents lists available at ScienceDirect

Practical Laboratory Medicine

journal homepage: www.elsevier.com/locate/plabm

Circulating markers of ageing and allostatic load: A slow train coming[☆]



Paul G. Shiels^a, Peter Stenvinkel^b, Jeroen P. Kooman^c, Dagmara McGuinness^{a,*}

^a University of Glasgow, Institute of Cancer Sciences, Wolfson-Wohl Translational Cancer Research Centre, Glasgow, UK

^b Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Huddinge, Sweden

^c Department of Internal Medicine, Division of Nephrology, Maastricht University Medical Center, Maastricht, Netherlands

ARTICLE INFO

Keywords:

Ageing
Allostatic load
Exosomes
Chronic kidney disease

ABSTRACT

Dealing with the growing burden of age-related morbidities is one of the greatest challenges facing modern society. How we age across the lifecourse and how psychosocial and lifestyle factors interplay with the biology of ageing remains to be fully elucidated. Sensitive and specific biomarkers with which to interrogate the biology of the ageing process are sparse. Recent evidence suggests that non-coding RNAs are key determinants of such processes and that these can be used as potential circulatory bio-markers of ageing. They may also provide a mechanism which mediates the spread of allostatic load across the body over time, ultimately reflecting the immunological health and physiological status of tissues and organs. The interplay between exosomal microRNAs and ageing processes is still relatively unexplored, although circulating microRNAs have been linked to the regulation of a range of physiological and pathological processes and offer insight into mechanistic determinants of healthspan.

1. Introduction

Physiological, cellular and psychological changes over the life course inevitably lead to the impaired function of an organism [1]. These changes are currently considered to be leading risk factors for the development of a range of morbidities. As the global population distribution shows a growing preponderance of elderly individuals, by 2050 those aged over 65 years are expected to outnumber children below 15 years of age (<http://www.who.int/world-health-day/2012/toolkit/background/en/>). This shift will bring with it an elevated burden of age-related disease and will represent a major drain on health care resources worldwide.

Conceptualization of the underlying mechanisms of ageing has identified nine hallmarks [1] comprising: genomic instability, telomere shortening, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, senescence, stem cell exhaustion and alterations in intercellular communication. However, not all of these hallmarks have been validated in clinical studies. Although research into the mechanisms of ageing processes is very dynamic there is still a pressing need for better understanding of ageing throughout the lifecourse. This is pertinent in the context of age-related morbidities and their relationship with psychosocial, nutritional and lifestyle factors, as well as with genetic and epigenetic determinants of ageing [2,3]. It

[☆] INVITED COMMENTARY, based on a presentation given at the Circulating Biomarkers 2015 Glasgow conference organized by Biotexcel Limited (Manchester, UK) on 30 September/1 October 2015.

* Correspondence to: University of Glasgow, Wolfson Wohl Translational Research Centre, Institute of Cancer Sciences, Garscube Estate, Switchback Road, Glasgow, G61 1QH, UK.

E-mail address: Dagmara.McGuinness@glasgow.ac.uk (D. McGuinness).

<http://dx.doi.org/10.1016/j.plabm.2016.04.002>

Received 12 April 2016; Accepted 15 April 2016

Available online 19 April 2016

2352-5517/ © 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

still remains to be determined whether such factors act cumulatively, interactively or individually, in predisposition and progression of age related disease. We will now discuss how these factors might interplay and how they might regulate ageing processes across organ systems through the life course.

Many age-related morbidities share an underlying pathophysiological mechanism linked to ageing processes and thus present with a premature ageing phenotype [4,5]. Such phenotypes can be a direct result of disruption of cellular homeostasis, which can be further accelerated by both environmental factors and intrinsic metabolic activity leading to the generation of oxidative stress/damage, endoplasmic reticulum stress and mitochondrial dysfunction [3,6]. The cumulative result of this burden of stress and the consequent adaptation to maintain and restore physiological homeostasis through physiological or behavioural changes has been termed allostasis [7]. Constant activation, or overload of allostatic mechanisms, results in systemic problems. Allostasis adaptation in chronic age-associated diseases, for example, may result in an increase in oxidative stress, an increase in the activity of innate immunity and constant low-grade inflammation [2]. This is in keeping with the hypothesis that cellular dysregulation is a catalyst for accelerated ageing and can be considered a disease-causing agent [8].

A direct link between increasing allostatic load and all-cause mortality has been established in longitudinal studies [9]. Links between allostatic load and specific health outcomes or disease (cardiovascular disease, diabetes, osteoporosis, chronic kidney disease and chronic obstructive pulmonary disease), as well as a general decline in physical and cognitive function, have also been established [4, 10–13]. Furthermore, the occurrence of age-related disorders has also been linked with the dysregulation of normal immune responses involved in the clearance of resident senescent cells within tissues. These cells are characterised by loss of proliferative function, resistance to death signals and promiscuous gene expression profiles [14], allowing their accumulation in aged organs/organisms. This situation has been observed across a broad range of degenerative disorders, including progeroid mice and also in cancer cells, suggesting that the selective removal of senescent cells *via* immune surveillance might be associated with delayed age-related deterioration [14–16].

2. Biomarkers of ageing

The ageing process is characterised by the presence of high inter-individual variation between individuals of the same chronological age; therefore there is an urgent need to identify informative biomarkers of ageing (BoA) to monitor the underlying molecular changes associated with ageing. The American Federation for Aging Research (AFAR) have proposed criteria for BoAs for ageing research; these state that a BoA must: (i) predict the rate of ageing and be a better predictor of lifespan than chronological age; (ii) monitor a basic process that underlies the ageing process, not the effects of disease; (iii) be able to be tested repeatedly without harming the individual; and (iv) be measurable in humans and in laboratory animals [17].

A sequitur for any valid BoA, under these criteria, would be that it shows a statistically significant association with a measure of health or organ functional capacity and chronological age. Furthermore, such a relationship must be statistically significant for all three pairwise associations. This is critical when applying BoA in the context of morbidities; features related to a specific morbidity must be delineated from those of the ageing process *per se*. Consequently, there is a paucity of biomarkers fulfilling these criteria in any robust fashion.

Recent approaches to identify more robust biomarkers have focussed on using renal allografts as a source of healthy tissue whose function can be followed longitudinally and in which context BoA can be compared 'head to head'. This approach initially identified CDKN2A expression as a robust biomarker, outperforming telomere length (a more traditional biomarker of ageing) in explaining inter-individual variation in renal function with age. Notably, many putative BoA identified in studies in model organisms failed to meet the AFAR criteria in the human specific renal system, indicating that they were more intimately linked to disease processes rather than ageing [18–21].

More recently, epigenetic analyses of the ageing process has led to the identification of a small number of micro RNAs (miRNAs), regulating the CDKN2 locus and associated with biochemical pathways implicated in regulating organismal longevity [22]. Critically, these miRNAs regulate common cellular metabolic pathways linked to nutritional stress, DNA repair processes, autophagy and protein synthesis. Moreover, these biochemical functions are common across taxa, indicating the substantive biological commonality in fundamental ageing processes. These observations are in keeping with the original mitochondrion/telomere nucleoprotein complex/ribosome (MTR) postulate of Shiels and Davies [24], whereby cellular ageing processes are linked tightly to macromolecular damage responses, energy availability and utilization [23,24]. The question remains, however, as to how one can extrapolate markers of cellular ageing to the ageing of the whole organism and whether these markers remain reflective of allostatic load, or reflect ongoing aspects of more local disease processes? This is particularly pertinent in the context of segmental ageing, where individual genes, such as those that give rise to unimodal progerias (*e.g.* WRN, Lamin A, BLM [25,26]) or genetic pathways that extend lifespan (*e.g.* mechanistic target of rapamycin [mTOR]) are likely to have non-uniform and non-cell-autonomous effects on the decline in tissue and organ function with increasing age. By extension, this implies that there is a direct interconnection between separate systems for tissue/organ and organismal ageing. In this context, regulation of circadian rhythms at a cellular, tissue and organismal level may provide an appropriate paradigm [2,3]. Of note, under the aegis of such a hypothesis, interventions to combat age-related decline in organ and tissue function might have unintended adverse consequences. By way of illustration, the use of caloric restriction to improve healthspan, for example, has resulted in a reduction in bone mineral density [27].

3. Exosomes, ageing and allostatic load

How ageing in one organ spreads its effects across the whole body and contributes to organismal allostatic load is an area of intense investigation. The BoA signature of age-related healthy renal function points towards epigenetic regulation as being a key feature of such a process. This is pertinent to the capacity of extracellular secretory vesicles (ESVs) to impact on non-cell autonomous ageing processes, which may be coupled with autophagy. A key class of such ESVs subject to much investigation are exosomes.

Exosomes are small, extracellular secretory vesicles (30–100 nm) containing a membranous lipid bilayer and originating from intercellular endosomal compartments, the contents of which vary significantly between cell types [28–30]. These have been demonstrated to facilitate intercellular communication, including stimulation of immune responses to promote wound healing [31] and may have a role in maintaining tissue homeostasis. Exosomes have also been postulated as a therapeutic vehicle to treat diseases of ageing, such as diabetes [32,33], cardiovascular disease [34], Alzheimer's disease [35] and chronic kidney disease [36–38].

Interestingly, altered miRNA profiles and lysosomal profiles have also been found in exosomes collected from subjects diagnosed with diseases of ageing, such as Parkinson's and Alzheimer's diseases [39,40]. The presence of misfolded proteins in exosomes, particularly prion-like proteins, has also been demonstrated in other neurodegenerative diseases including Creutzfeldt-Jakob disease [41].

There is a growing body of evidence demonstrating modulation of exosomal contents by stress induction [42], which may impact the lifecourse, and therefore will be associated with allostatic load and driven by ageing. These modulators include both biophysical and metabolic stressors, such as nutrient deprivation [43], heat [44], hypoxia, or irradiation [45]. Critically, following on from a thesis that stress accelerates ageing and that early onset of diseases of ageing result from this, exosomal contents are modified by several of the “stress” hormones. For example, corticosteroid can induce myocilin (MYOC), which is linked to glaucoma [46]. Glucocorticoid stimulation can also increase the levels of specific miRNAs namely miR-23a [47] and miR-182 [48] within exosomes without influencing the secretion levels of exosomes overall. These miRNAs have also been linked to regulation of FOXP3 and calcineurin signalling in muscle atrophy and muscle wasting.

These observations are pertinent to psychosocial and lifestyle factors, which are both associated with the accrual of allostatic load and the acceleration of ageing [4,49–51] and may link accelerated ageing with poor nutrition and inflammation, both at a cellular level and at a general population level.

This association with inflammation and nutrition has been further strengthened by the observations that hyperphosphataemia, a proven cause of accelerated ageing in mammals [52–55], is nutritionally driven. Furthermore, it is linked to accelerated ageing and early onset disease in man and associated with the frequency of red meat consumption in a setting of social deprivation [56]. The importance of phosphate in the accelerated ageing phenotype can be linked to vascular calcification and formation of cytotoxic calciprotein particles (CPPs), a common feature of many metabolic and accelerated ageing syndromes. Since phosphate activates the ACT/mTORC1 blockade of mTORC1 may have therapeutic potential for premature aging-like symptoms [57]. Vascular calcification, a common feature in the ageing process, can be counteracted by Fetuin A, a putative marker of ageing, characterised by reduced concentration in a number of pathologies associated with accelerated ageing including chronic kidney disease and cancer [58–60]. Recent *in vivo* and *in vitro* results also suggest that lamin A plays an important role in the process of premature vascular ageing [61]. Recent studies investigating the role of senescent associated phenotype (SASP) in smooth vascular cell ageing has revealed that changes in expression and contents of exosomes are associated with vascular calcification [62]. Exosomes generated from senescent vascular smooth muscle cells are altered in terms of the proteins, miRNAs and minerals they contain [62]. These exosomes directly drive the disease pathology, demonstrated by blocking of exosome secretion and subsequent amelioration of pathology [63].

The link between ageing, inflammation and nutrition is also pertinent to non-coding RNA regulation of healthy ageing processes [64]. Recently, changes in both circulating and membrane marker levels, used to classify a broad range of extracellular vesicles (EVs) including exosomes, have been observed in association with age-related structural and functional changes in solid organs, [65]. In this context, the exosomal secretome from senescent cells has been hypothesized as a potential contributor to age-associated inflammation and decline in immune function [66–72]. This, when coupled with DNA damage response (DDR) signaling, has been implicated in the generation of pro-inflammatory senescence-associated secretory phenotype (SASP). The relative contribution of the SASP to age-related inflammatory status, while intuitive, has proved to be modest in general population cohort studies, where BoAs, such as telomere length in circulating leukocytes, have explained less than 10% of inter-individual variation in inflammatory status [51,73–75].

The contribution of exosomal non-coding RNAs in this context remains to be proven, but might well help to explain a greater proportion of this inter-individual variation in the inflammatory status or a correlative predisposition to age-related diseases [72]. Additionally, it may help to explain how exosomes are able to generate a pro-tumor environment that is essential for carcinogenesis through maintenance of an oncogenic niche and modulation of immune function [76].

4. Conclusions

Modulation of the ageing process over the lifecourse is complex, comprising advertent regulation of a range of biochemical processes *via* psychosocial, lifestyle and nutritional factors in association with genetic and epigenetic determinants of ageing.

The cumulative result of their actions is morbidity and eventual mortality. A range of biomarker studies, as we have described, indicates that the accumulation of senescent cells results in decreased tissue and organ function, increased allostatic load and accompanying inflammatory burden. The epigenetic component, which has the capacity to transmit both intergenerationally and transgenerationally, is particularly intriguing, as it may act as the body's hamartia in facilitating the spread of allostatic load across the whole organism. Consequently, this process may, through the transmission of exosome non-coding RNAs, help regulate niches for the progression and spread of disease as well as providing system-wide cues for allostatic responses. The expression, composition and function of exosomes are modulated by a range of stress hormones enabling a dynamic response to environmental triggers at a cellular level. As such, their modulation may serve as an excellent target for future therapeutic interventions in reducing age-related morbidities and improving health span. It is also likely that better understanding of the biology of exceptionally long-lived animals, such as naked mole rats, which possess a 30 year lifespan, will contribute to better understanding of ageing processes [5].

References

- [1] C. López-Otín, M.A. Blasco, L. Partridge, M. Serrano, G. Kroemer, The hallmarks of aging, *Cell* 153 (2013) 1194–1217. <http://dx.doi.org/10.1016/j.cell.2013.05.039>.
- [2] J.P. Kooman, P. Kotanko, A.M.W.J. Schols, P.G. Shiels, P. Stenvinkel, Chronic kidney disease and premature ageing, *Nat. Rev. Nephrol.* 10 (2014) 732–742. <http://dx.doi.org/10.1038/nrneph.2014.185>.
- [3] P.G. Shiels, K. Ritzau-Reid, Biological Ageing, Inflammation and Nutrition: How Might They Impact on Systemic Sclerosis?, *Curr. Aging Sci.* 8 (2015) 123–130.
- [4] J.P. Kooman, P.G. Shiels, P. Stenvinkel, Premature aging in chronic kidney disease and chronic obstructive pulmonary disease: similarities and differences, *Curr. Opin. Clin. Nutr. Metab. Care* 18 (2015) 528–534. <http://dx.doi.org/10.1097/MCO.0000000000000218>.
- [5] P. Stenvinkel, J.P. Kooman, P.G. Shiels, Nutrients and ageing: what can we learn about ageing interactions from animal biology?, *Curr. Opin. Clin. Nutr. Metab. Care* 19 (2016) 19–25. <http://dx.doi.org/10.1097/MCO.0000000000000234>.
- [6] D. Gems, The aging-disease false dichotomy: understanding senescence as pathology, *Front. Genet.* 6 (2015). <http://dx.doi.org/10.3389/fgene.2015.00212>.
- [7] J. Eyer, P. Sterling, Allostasis: a new paradigm to explain arousal pathology, in: S. Fisher, J. Reason (Eds.), *Handbook Life Stress, Cognition Health*, John Wiley & Sons, New York, 1988, pp. 629–649.
- [8] R.-P. Juster, B.S. McEwen, S.J. Lupien, Allostatic load biomarkers of chronic stress and impact on health and cognition, *Neurosci. Biobehav. Rev.* 35 (2010) 2–16. <http://dx.doi.org/10.1016/j.neubiorev.2009.10.002>.
- [9] A.S. Karlamangla, B.H. Singer, T.E. Seeman, Reduction in allostatic load in older adults is associated with lower all-cause mortality risk: MacArthur studies of successful aging, *Psychosom. Med.* 68 (2006) 500–507. <http://dx.doi.org/10.1097/01.psy.0000221270.93985.82>.
- [10] S.L. Brennan-Olsen, R.S. Page, M. Berk, J.A. Riancho, W.D. Leslie, S.G. Wilson, et al., DNA methylation and the social gradient of osteoporotic fracture: a conceptual model, *Bone* 84 (2016) 204–212. <http://dx.doi.org/10.1016/j.bone.2015.12.015>.
- [11] D.S. Goldstein, Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease, *Adv. Pharmacol.* 68 (2013) 235–272. <http://dx.doi.org/10.1016/B978-0-12-411512-5.00012-9>.
- [12] J. Mattei, S. Demissie, L.M. Falcon, J.M. Ordovas, K. Tucker, Allostatic load is associated with chronic conditions in the Boston Puerto Rican Health Study, *Soc. Sci. Med.* 70 (2010) (1982) 1988–1996. <http://dx.doi.org/10.1016/j.socscimed.2010.02.024>.
- [13] T.E. Seeman, B.S. McEwen, J.W. Rowe, B.H. Singer, Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging, *Proc. Natl. Acad. Sci. USA* 98 (2001) 4770–4775. <http://dx.doi.org/10.1073/pnas.081072698>.
- [14] D.G.A. Burton, R.G.A. Faragher, Cellular senescence: from growth arrest to immunogenic conversion, *Age* 37 (2015) 27. <http://dx.doi.org/10.1007/s11357-015-9764-2>.
- [15] J. Campisi, F. d'Adda di Fagagna, Cellular senescence: when bad things happen to good cells, *Nat. Rev. Mol. Cell Biol.* 8 (2007) 729–740. <http://dx.doi.org/10.1038/nrm2233>.
- [16] Y. Ovadya, V. Krizhanovsky, Senescent cells: SASPected drivers of age-related pathologies, *BioGerontology* 15 (2014) 627–642. <http://dx.doi.org/10.1007/s10522-014-9529-9>.
- [17] A. Bürkle, M. Moreno-Villanueva, J. Bernhard, M. Blasco, G. Zondag, J.H.J. Hoeijmakers, et al., MARK-AGE biomarkers of ageing, *Mech. Ageing Dev.* 151 (2015) 2–12. <http://dx.doi.org/10.1016/j.mad.2015.03.006>.
- [18] M. Gingell-Littlejohn, D. McGuinness, L.M. McGlynn, D. Kingsmore, K.S. Stevenson, C. Koppeltaetter, et al., Pre-transplant CDKN2A expression in kidney biopsies predicts renal function and is a future component of donor scoring criteria, *Plos One* 8 (2013) e68133. <http://dx.doi.org/10.1371/journal.pone.0068133>.
- [19] C. Koppeltaetter, G. Schratzberger, P. Perco, J. Hofer, W. Mark, R. Ollinger, et al., Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation, *Aging Cell* 7 (2008) 491–497. <http://dx.doi.org/10.1111/j.1474-9726.2008.00398.x>.
- [20] K.J. Lamb, P.G. Shiels, Telomeres, ageing and oxidation, *SEB Exp. Biol. Ser.* 62 (2009) 117–137.
- [21] L.M. McGlynn, K. Stevenson, K. Lamb, S. Zino, M. Brown, A. Prina, et al., Cellular senescence in pretransplant renal biopsies predicts postoperative organ function, *Aging Cell* 8 (2009) 45–51. <http://dx.doi.org/10.1111/j.1474-9726.2008.00447.x>.
- [22] D. McGuinness, J. Leierer, O. Shapter, S. Mohammed, M. Gingell-Littlejohn, D.B. Kingsmore, et al., Identification of Molecular Markers of Delayed Graft Function Based on the Regulation of Biological Ageing, *Plos One* 11 (2016) e0146378. <http://dx.doi.org/10.1371/journal.pone.0146378>.
- [23] D. McGuinness, D.H. McGuinness, J.A. McCaul, P.G. Shiels, Sirtuins, bioageing, and cancer, *J. Aging Res.* 2011, 235754 (2011). <http://dx.doi.org/10.4061/2011/235754>.
- [24] P.G. Shiels, R.W. Davies, Ageing and Death in Neurons, in: *Molecular Biology of the Neuron*, 2nd ed., 2003, pp. 436–464.
- [25] O. Dreesen, C.L. Stewart, Accelerated aging syndromes, are they relevant to normal human aging?, *Aging* 3 (2011) 889–895.
- [26] R. Vaitiekunaite, D. Butkiewicz, M. Krześniak, M. Przybyłek, A. Gryc, M. Sniatura, et al., Expression and localization of Werner syndrome protein is modulated by SIRT1 and PML, *Mech. Ageing Dev.* 128 (2007) 650–661. <http://dx.doi.org/10.1016/j.mad.2007.09.004>.
- [27] D.T. Villareal, J.J. Kotyk, R.C. Armamento-Villareal, V. Kenguva, P. Seaman, A. Shahar, et al., Reduced bone mineral density is not associated with significantly reduced bone quality in men and women practicing long-term calorie restriction with adequate nutrition, *Aging Cell* 10 (2011) 96–102. <http://dx.doi.org/10.1111/j.1474-9726.2010.00643.x>.
- [28] D.F. Anthony, P.G. Shiels, Exploiting paracrine mechanisms of tissue regeneration to repair damaged organs, *Transplant. Res.* 2 (2013) 10. <http://dx.doi.org/10.1186/2047-1440-2-10>.
- [29] P. Bastos-Amador, F. Royo, E. Gonzalez, J. Conde-Vancells, L. Palomo-Diez, F.E. Borrás, et al., Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability, *J. Proteom.* 75 (2012) 3574–3584. <http://dx.doi.org/10.1016/j.jprot.2012.03.054>.
- [30] C. Théry, M. Ostrowski, E. Segura, Membrane vesicles as conveyors of immune responses, *Nat. Rev. Immunol.* 9 (2009) 581–593. <http://dx.doi.org/10.1038/nri2567>.
- [31] G. Raposo, H.W. Nijman, W. Stoorvogel, R. Liejendekker, C.V. Harding, C.J. Melief, et al., B lymphocytes secrete antigen-presenting vesicles, *J. Exp. Med.* 183 (1996) 1161–1172. <http://dx.doi.org/10.1084/jem.183.3.1161>.
- [32] D. McGuinness, D.F. Anthony, V. Moulisova, A.I. MacDonald, A. MacIntyre, J. Thomson, et al., Microvesicles but not exosomes from pathfinder cells stimulate functional recovery of the pancreas in a mouse streptozotocin-induced diabetes model, *Rejuv. Res.* (2016). <http://dx.doi.org/10.1089/rej.2015.1723>.
- [33] H. Xin, Y. Li, Z. Liu, X. Wang, X. Shang, Y. Cui, et al., MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles, *Stem Cells* 31 (2013) 2737–2746. <http://dx.doi.org/10.1002/>

- stem.1409.
- [34] L. Huang, W. Ma, Y. Ma, D. Feng, H. Chen, B. Cai, Exosomes in mesenchymal stem cells, a new therapeutic strategy for cardiovascular diseases?, *Int. J. Biol. Sci.* 11 (2015) 238–245. <http://dx.doi.org/10.7150/ijbs.10725>.
- [35] T. Katsuda, K. Oki, T. Ochiya, Potential application of extracellular vesicles of human adipose tissue-derived mesenchymal stem cells in Alzheimer's disease Therapeutics, in: K. Turksen (Ed.) *Stem Cell Renewal and Cell-Cell Communication*, Springer, New York, NY, 2014, pp. 171–181 (accessed 12.04.16) http://link.springer.com/10.1007/97812014_918.
- [36] G. Camussi, M.C. Deregibus, V. Cantaluppi, Role of stem-cell-derived microvesicles in the paracrine action of stem cells, *Biochem. Soc. Trans.* 41 (2013) 283–287. <http://dx.doi.org/10.1042/BST20120192>.
- [37] P.J. Quesenberry, J. Aliotta, M.C. Deregibus, G. Camussi, Role of extracellular RNA-carrying vesicles in cell differentiation and reprogramming, *Stem Cell Res. Ther.* 6 (2015) 153. <http://dx.doi.org/10.1186/s13287-015-0150-x>.
- [38] P.J. Quesenberry, L.R. Goldberg, J.M. Aliotta, M.S. Dooner, M.G. Pereira, S. Wen, et al., Cellular phenotype and extracellular vesicles: basic and clinical considerations, *Stem Cells Dev.* 23 (2014) 1429–1436. <http://dx.doi.org/10.1089/scd.2013.0594>.
- [39] E.J. Goetzl, A. Boxer, J.B. Schwartz, E.L. Abner, R.C. Petersen, B.L. Miller, et al., Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease, *Neurology* 85 (2015) 40–47. <http://dx.doi.org/10.1212/WNL.0000000000001702>.
- [40] Y. Gui, H. Liu, L. Zhang, W. Lv, X. Hu, Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease, *Oncotarget* 6 (2015) 37043–37053. <http://dx.doi.org/10.18632/oncotarget.6158>.
- [41] B.M. Coleman, A.F. Hill, Extracellular vesicles – Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases, *Semin. Cell Dev. Biol.* 40 (2015) 89–96. <http://dx.doi.org/10.1016/j.semcdb.2015.02.007>.
- [42] L.A. Beninson, M. Fleshner, Exosomes: An emerging factor in stress-induced immunomodulation, *Semin. Immunol.* 26 (2014) 394–401. <http://dx.doi.org/10.1016/j.smim.2013.12.001>.
- [43] C. Théry, S. Amigorena, G. Raposo, A. Clayton, Isolation and characterization of exosomes from cell culture supernatants and biological fluids, in: J.S. Bonifacio, M. Dasso, J.B. Harford, J. Lippincott-Schwartz, K.M. Yamada (Eds.), *Current Protocols in Cell Biology*, John Wiley & Sons, Inc., Hoboken, NJ, USA, 2006 (accessed 29.02.16) <http://doi.wiley.com/10.1002/0471143030.cb0322s30>.
- [44] T. Chen, J. Guo, M. Yang, X. Zhu, X. Cao, Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine, *J. Immunol.* 186 (2011) 2219–2228. <http://dx.doi.org/10.4049/jimmunol.1002991>.
- [45] J. Ratajczak, M. Wysocki, F. Hayek, A. Janowska-Wieczorek, M.Z. Ratajczak, Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication, *Leukemia* 20 (2006) 1487–1495. <http://dx.doi.org/10.1038/sj.leu.2404296>.
- [46] E.A. Hoffman, K.M. Perikuma, L.M. Highstrom, W.D. Stamer, Regulation of myocilin-associated exosome release from human trabecular meshwork cells, *Investig. Ophthalmol. Vis. Sci.* 50 (2009) 1313. <http://dx.doi.org/10.1167/iovs.08-2326>.
- [47] M.B. Hudson, M.E. Woodworth-Hobbs, B. Zheng, J.A. Rahner, M.A. Blount, J.L. Gooch, et al., miR-23a is decreased during muscle atrophy by a mechanism that includes calcineurin signaling and exosome-mediated export, *Am. J. Physiol. Cell Physiol.* 306 (2014) C551–C558. <http://dx.doi.org/10.1152/ajpcell.00266.2013>.
- [48] M.B. Hudson, J.A. Rahner, B. Zheng, M.E. Woodworth-Hobbs, H.A. Franch, S. Russ Price, miR-182 attenuates atrophy-related gene expression by targeting FoxO3 in skeletal muscle, *Am. J. Physiol. Cell Physiol.* 307 (2014) C314–C319. <http://dx.doi.org/10.1152/ajpcell.00395.2013>.
- [49] L.F. Cherkas, A. Aviv, A.M. Valdes, J.L. Hunkin, J.P. Gardner, G.L. Surdulescu, et al., The effects of social status on biological aging as measured by white-blood-cell telomere length, *Aging Cell* 5 (2006) 361–365. <http://dx.doi.org/10.1111/j.1474-9726.2006.00222.x>.
- [50] D. McGuinness, L.M. McGlynn, P.C. Johnson, A. MacIntyre, G.D. Batty, H. Burns, et al., Socio-economic status is associated with epigenetic differences in the pSoBid cohort, *Int. J. Epidemiol.* 41 (2012) 151–160. <http://dx.doi.org/10.1093/ije/dyr215>.
- [51] P.G. Shiels, L.M. McGlynn, A. MacIntyre, P.C.D. Johnson, G.D. Batty, H. Burns, et al., Accelerated telomere attrition is associated with relative household income, diet and inflammation in the pSoBid cohort, *Plos One* 6 (2011) e22521. <http://dx.doi.org/10.1371/journal.pone.0022521>.
- [52] M. Kuro-O, K. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism, *Nat. Rev. Nephrol.* 9 (2013) 650–660. <http://dx.doi.org/10.1038/nrneph.2013.111>.
- [53] M. Kuro-O, A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease, *Kidney Int. Suppl.* 3 (2013) 420–426. <http://dx.doi.org/10.1038/kisup.2013.88>.
- [54] M. Ohnishi, T. Nakatani, B. Lanske, M.S. Razzaque, Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1 α -hydroxylase, *Kidney Int.* 75 (2009) 1166–1172. <http://dx.doi.org/10.1038/ki.2009.24>.
- [55] M. Ohnishi, M.S. Razzaque, Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging, *FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol.* 24 (2010) 3562–3571. <http://dx.doi.org/10.1096/fj.09-152488>.
- [56] R. McClelland, K. Christensen, S. Mohammed, D. McGuinness, J. Cooney, A. Bakshi, et al., Accelerated ageing and renal dysfunction links lower socioeconomic status and dietary phosphate intake. *Ageing*, 2016.
- [57] M. Kawai, S. Kinoshita, K. Ozono, T. Michigami, Inorganic phosphate activates the AKT/mTORC1 pathway and shortens the life span of an α -klotho-deficient model, *J. Am. Soc. Nephrol.* (2016). <http://dx.doi.org/10.1681/ASN.2015040446>.
- [58] J.J. Carrero, P. Stenvinkel, B. Fellström, A.R. Qureshi, K. Lamb, O. Heimbürger, et al., Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients, *J. Intern. Med.* 263 (2008) 302–312. <http://dx.doi.org/10.1111/j.1365-2796.2007.01890.x>.
- [59] F. Maxwell, L.M. McGlynn, H.C. Muir, D. Talwar, M. Benzeval, T. Robertson, et al., Telomere attrition and decreased fetuin-A levels indicate accelerated biological aging and are implicated in the pathogenesis of colorectal cancer, *Clin. Cancer Res.* 17 (2011) 5573–5581. <http://dx.doi.org/10.1158/1078-0432.CCR-10-3271>.
- [60] M.A. Merideth, L.B. Gordon, S. Clauss, V. Sachdev, A.C.M. Smith, M.B. Perry, et al., Phenotype and course of Hutchinson–Gilford progeria syndrome, *N. Engl. J. Med.* 358 (2008) 592–604. <http://dx.doi.org/10.1056/NEJMoa0706898>.
- [61] I. Quirós-González, P. Román-García, C. Alonso-Montes, S. Barrio-Vázquez, N. Carrillo-López, M. Naves-Díaz, et al., Lamin A is involved in the development of vascular calcification induced by chronic kidney failure and phosphorus load, *Bone* 84 (2016) 160–168. <http://dx.doi.org/10.1016/j.bone.2016.01.005>.
- [62] A.N. Kapustin, C.M. Shanahan, Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation, *J. Physiol.* (2016). <http://dx.doi.org/10.1113/JP271340>.
- [63] A.N. Kapustin, M.L.L. Chatrou, I. Drozdov, Y. Zheng, S.M. Davidson, D. Soong, et al., Vascular smooth muscle cell calcification is mediated by regulated exosome secretion, *Circ. Res.* 116 (2015) 1312–1323. <http://dx.doi.org/10.1161/CIRCRESAHA.116.305012>.
- [64] K. Szarec vel Sziec, K. Declercq, M. Vidaković, W. Vanden Bergh, From inflammation to healthy aging by dietary lifestyle choices: is epigenetics the key to personalized nutrition?, *Clin. Epigenetics* 7 (2015) 33. <http://dx.doi.org/10.1186/s13148-015-0068-2>.
- [65] A.E. Turco, W. Lam, A.D. Rule, A. Demic, J.C. Lieske, V.M. Miller, et al., Specific renal parenchymal-derived urinary extracellular vesicles identify age-associated structural changes in living donor kidneys, *J. Extracell. Vesicles* 5 (2016) 29642.
- [66] M.E. Bauer, M.D. la Fuente, The role of oxidative and inflammatory stress and persistent viral infections in immunosenescence, *Mech. Ageing Dev.* (2016). <http://dx.doi.org/10.1016/j.mad.2016.01.001>.
- [67] M. Deleidi, M. Jäggle, G. Rubino, Immune aging, dysmetabolism, and inflammation in neurological diseases, *Front. Neurosci.* 9 (2015) 172. <http://dx.doi.org/10.3389/fnins.2015.00172>.
- [68] T. Fulop, A. Le Page, C. Fortin, J.M. Witkowski, G. Dupuis, A. Larbi, Cellular signaling in the aging immune system, *Curr. Opin. Immunol.* 29 (2014) 105–111. <http://dx.doi.org/10.1016/j.coi.2014.05.007>.
- [69] J. Hazeldine, J.M. Lord, P. Hampson, Immunosenescence and inflammaging: A contributory factor in the poor outcome of the geriatric trauma patient, *Ageing Res. Rev.* 24 (2015) 349–357. <http://dx.doi.org/10.1016/j.arr.2015.10.003>.
- [70] P.-J. Linton, M.L. Thoman, Immunosenescence in monocytes, macrophages, and dendritic cells: lessons learned from the lung and heart, *Immunol. Lett.* 162 (2014) 290–297. <http://dx.doi.org/10.1016/j.imlet.2014.06.017>.
- [71] P.L. Minicullo, A. Catalano, G. Mandraffino, M. Casciaro, A. Crucitti, G. Maltese, et al., Inflammaging and anti-Inflammaging: the role of cytokines in extreme longevity, *Arch. Immunol. Ther. Exp.* 64 (2016) 111–126. <http://dx.doi.org/10.1007/s00005-015-0377-3>.
- [72] F. Olivieri, M.C. Albertini, M. Orciani, A. Ceka, M. Cricca, A.D. Procopio, et al., DNA damage response (DDR) and senescence: shuttled inflamma-miRNAs on the stage of inflamm-aging, *Oncotarget* 6 (2015) 35509–35521. <http://dx.doi.org/10.18632/oncotarget.5899>.
- [73] A.C. Phillips, T. Robertson, D. Carroll, G. Der, P.G. Shiels, L. McGlynn, et al., Do symptoms of depression predict telomere length? Evidence from the West of

- Scotland Twenty-07 study, *Psychosom. Med.* 75 (2013) 288–296. <http://dx.doi.org/10.1097/PSY.0b013e318289e6b5>.
- [74] T. Robertson, G.D. Batty, G. Der, M.J. Green, L.M. McGlynn, A. McIntyre, et al., Is telomere length socially patterned? Evidence from the West of Scotland Twenty-07 Study, *Plos One* 7 (2012) e41805. <http://dx.doi.org/10.1371/journal.pone.0041805>.
- [75] M.W. Robinson, D. McGuinness, R. Swann, S. Barclay, P.R. Mills, A.H. Patel, et al., Non cell autonomous upregulation of CDKN2 transcription linked to progression of chronic hepatitis C disease, *Aging Cell* 12 (2013) 1141–1143. <http://dx.doi.org/10.1111/acer.12125>.
- [76] J.A. Tickner, A.J. Urquhart, S.-A. Stephenson, D.J. Richard, K.J. O'Byrne, Functions and Therapeutic Roles of Exosomes in Cancer, *Front. Oncol.* 4 (2014). <http://dx.doi.org/10.3389/fonc.2014.00127>.